TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole

Pharmacogenomics

Volumn 10, Issue 4, 2009, Pages 531-540

  Alfirevic, Ana ^a   Vilar, F Javier ^b   Alsbou, Mohammed ^a   Jawaid, Ansar ^c   Thomson, Wendy ^d   Ollier, William E R ^d   Bowman, Clive E ^e   Delrieu, Olivier ^f   Park, B Kevin ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF READING   (United Kingdom)

^f Pharmacogenomics Innovative Solutions   (United Kingdom)

Author keywords

Adverse drug reactions; Cotrimoxazole; HIV; HLA; Hypersensitivity; MHC region; Polymorphisms; Sulphametoxazole

Indexed keywords

COTRIMOXAZOLE; SULFAMETHOXAZOLE;

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENOTYPE; HAPLOTYPE; HLA DR GENE; HSPA1L GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOPATHOGENESIS; LOW DRUG DOSE; LTA GENE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PNEUMOCYSTIS PNEUMONIA; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TNF GENE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; DRUG HYPERSENSITIVITY; FEMALE; HAPLOTYPES; HLA-DR ANTIGENS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOTOXIN-ALPHA; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66849142469     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.6     Document Type: Article

References (71)

1. Schneider MM, Nielsen TL, Nelsing S et al.: Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J. Infect. Dis. 171, 1632-1636 (1995).
2. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF: Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 19, 163-168 (2005).
3. Wiktor SZ, Sassan-Morokro M, Grant AD et al.: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infiected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 353, 1469-1475 (1999).
4. World Health Organisation: Guidelines on co-trimoxazoleprophylaxis for HIV-related infections among children, adolescents and adults. WHO, Geneva, Switzerland (2006).
5. Bigby M, Jick S, Jick H, Arndt K: Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256, 3358-3363 (1986).
6. Gordin FM, Simon GL, Wofsy CB, Mills J: Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 100, 495-499 (1984).
7. Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA: Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 2, 1109-1111 (1983).
8. Carr A, Penny R, Cooper DA: Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 7, 65-71 (1993).
9. + T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. 155, 462-472 (1995).
10. Nassif A, Bensussan A, Dorothee G et al.: Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118, 728-733 (2002).
11. + T-cells. Br. J. Pharmacol. 132, 623-630 (2001).
12. Naisbitt DJ, Farrell J, Gordon SF et al.: Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 62, 628-637 (2002).
13. Nassif A, Moslehi H, Le Gouvello S et al.: Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J. Invest. Dermatol. 123, 850-855 (2004).
14. Paquet P, Pierard GE: Soluble fractions of tumor necrosis factor-α, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int. J. Mol. Med. 1, 459-462 (1998).
15. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
16. Hetherington S, Hughes AR, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
17. Hetherington S, McGuirk S, Powell G et al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614 (2001).
18. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
19. Martin AM, Nolan D, Gaudieri S et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101, 4180-4185 (2004).
20. Martin AM, Nolan D, James I et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19, 97-99 (2005).
21. Pirmohamed M, Lin K, Chadwick D, Park BK: TNF-α promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56, 890-896 (2001).
22. Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology 209, 123-129 (2005).
23. Pirmohamed M, Alfirevic A, Vilar J et al.: Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 10, 705-713 (2000).
24. Wolkenstein P, Loriot MA, Flahault A et al.: Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides. J. Invest. Dermatol. 125, 1080-1082 (2005).
25. Bhaiya P, Roychowdhury S, Vyas PM, Doll MA, Hein DW, Svensson CK: Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts. Toxicol. Appl. Pharmacol. 215, 158-167 (2006).
26. Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, Svensson CK: Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J. Pharmacol. Exp. Ther. 314, 43-52 (2005).
27. Roychowdhury S, Vyas PM, Svensson CK: Formation and uptake of arylhydroxylamine-haptenated proteins in human dendritic cells. Drug Metab. Dispos. 35, 676-681 (2007).
28. Alfirevic A, Mills T, Harrington P et al.: Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet. Genomics 16, 287-296 (2006).
29. Knight JC, Keating BJ, Kwiatkowski DP: Allele-specific repression of lymphotoxin-α by activated B cell factor-1. Nat. Genet. 36, 394-399 (2004).
30. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP: In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat. Genet. 33, 469-475 (2003).
31. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M: Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br. J. Clin. Pharmacol. 55, 158-165 (2003).
32. Grove J, Daly AK, Bassendine MF, Day CP: Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26, 143-146 (1997).
33. Schroder O, Schulte KM, Ostermann P, Roher HD, Ekkernkamp A, Laun RA: Heat shock protein 70 genotypes HSPA1B and HSPA1L influence cytokine concentrations and interfere with outcome after major injury. Crit. Care Med. 31, 73-79 (2003).
34. Wilson AG, Clay FE, Crane AM, Cork MJ, Duff GW: Comparative genetic association of human leukocyte antigen class II and tumor necrosis factor-α with dermatitis herpetiformis. J. Invest. Dermatol. 104, 856-858 (1995).
35. Thomson W, Ollier W. Non-radioactive ASO typing for class II - the way forward. Eur. J. Immunogenet. 19, 169-175 (1992).
36. Sham PC, Curtis D: Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59, 97-105 (1995).
37. Delrieu O, Bowman C: Visualizing gene determinants of disease in drug discovery. Pharmacogenomics 7, 311-329 (2006).
38. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14, 335-342 (2004).
39. Ozkaya-Bayazit E, Akar U: Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J. Am. Acad. Dermatol. 45, 712-717 (2001).
40. Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N: HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 28, 251-254 (1986).
41. Wolkenstein P, Carriere V, Charue D et al.: A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 5, 255-258 (1995).
42. Zielinska E, Niewiarowski W, Bodalski J et al.: Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants. Pharm. World Sci. 20, 123-130 (1998).
43. Carr A, Tindall B, Penny R, Cooper DA: In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin. Exp. Immunol. 94, 21-25 (1993).
44. Rieder MJ, King SM, Read S: Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 16, 1028-1031 (1997).
45. Cribb AE, Lee BL, Trepanier LA, Spielberg SP: Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React. Toxicol. Rev. 15, 9-50 (1996).
46. Lin D, Li WK, Rieder MJ: Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst. Rep. CD005646 (2007).
47. Eliaszewicz M, Flahault A, Roujeau JC et al.: Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J. Am. Acad. Dermatol. 47, 40-46 (2002).
48. 3: disease progression, treatment durability, and drug toxicity. Clin. Infect. Dis. 36, 812-815 (2003).
49. Gonzalez-Delgado P, Blanes M, Soriano V, Montoro D, Loeda C, Niveiro E: Erythema multiforme to amoxicillin with concurrent infection by Epstein-Barr virus. Allergol. Immunopathol. (Madr.) 34, 76-78 (2006).
50. Mulroy R: Amoxycillin rash in infectious mononucleosis. Br. Med. 1, 554 (1973).
51. Renn CN, Straff W, Dorfmuller A, Al-Masaoudi T, Merk HF, Sachs B: Amoxicillin-induced exanthema in young adults with infectious mononucleosis: demonstration of drug-specific lymphocyte reactivity. Br. J. Dermatol. 147, 1166-1170 (2002).
52. Conilleau V, Dompmartin A, Verneuil L, Michel M, Leroy D: Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis 41, 141-144 (1999).
53. Criado PR, Criado RF, Vasconcellos C, Pegas J R, Cera PC: Drug-induced hypersensitivity syndrome due to anticonvulsants in a two-year-old boy. J. Dermatol. 31, 1009-1013 (2004).
54. Ogihara T, Takahashi T, Hanihara T, Amano N, Matsumoto K: Carbamazepine-induced hypersensitivity syndrome, associated with human herpesvirus 6 reactivation. J. Clin. Psychopharmacol. 24, 105-106 (2004).
55. Oskay T, Karademir A, Erturk OI: Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6, 7. Epilepsy Res. 70, 27-40 (2006).
56. Arp J, Rieder MJ, Urquhart B et al.: Hypersensitivity of HIV-1-infected cells to reactive sulfonamide metabolites correlated to expression of the HIV-1 viral protein tat. J. Pharmacol. Exp. Ther. 314, 1218-1225 (2005).
57. Ahmad T, Neville M, Marshall SE et al.: Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum. Mol. Genet. 12, 647-656 (2003).
58. Hung SI, Chung WH, Jee SH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306 (2006).
59. Alfirevic A, Jorgensen AL, Williamson PR Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7, 813-818 (2006).
60. Lonjou C, Thomas L, Borot N et al.: A marker for Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J. 6, 265-268 (2006).
61. Hung SI, Chung WH, Liou LB et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134-4139 (2005).
62. Gibson JR: Recurrent trimethoprim-associated fixed skin eruption. BMJ (Clin. Res. Ed.) 284, 1529-1530 (1982).
63. Cribb AE, Spielberg SP, Griffin GP: N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23, 406-414 (1995).
64. Rieder MJ, Krause R, Bird IA, Dekaban GA: Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 134-140 (1995).
65. Lee BL, Wong D, Benowitz NL, Sullam PM: Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 53, 529-535 (1993).
66. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP: Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin. Pharmacol. Ther. 49, 13-17 (1991).
67. Cribb AE, Nuss CE, Alberts DW et al.: Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem. Res. Toxicol. 9, 500-507 (1996).
68. Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, Wells PG: Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS 11, 1689-1697 (1997).
69. Simon T, Becquemont L, Mary-Krause M et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 67, 432-437 (2000).
70. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, Park BK: Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res. Hum. Retroviruses 16, 1929-1938 (2000).
71. Sanderson JP, Naisbitt DJ, Farrell J et al.: Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J. Immunol. 178, 5533-5542 (2007).